Last reviewed · How we verify
Valyl (isovaleryl diethylamide)
Valyl (generic name: isovaleryl diethylamide) is a drug. It is currently in unknown development.
Valyl is thought to work by interacting with a specific molecular target, although the exact mechanism is currently unknown.
Valyl, also known as isovaleryl diethylamide, is a small molecule compound with unknown drug class and target. Its development and current ownership are not publicly disclosed. The compound's pharmacological properties, including its half-life, bioavailability, and approved indications, are also unknown. As a result, its commercial status and key safety considerations cannot be determined. Further research is needed to understand the compound's potential therapeutic applications and risks.
At a glance
| Generic name | isovaleryl diethylamide |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells have locks on them, and Valyl is a key that fits into one of those locks. When it binds, it can either turn the lock on or off, depending on the type of lock and the key's shape. This interaction can affect how cells behave and communicate with each other, potentially leading to changes in the body's response to certain stimuli.
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of Romidepsin in Combination With Parsaclisib in Relapsed and Refractory T-Cell Lymphomas (Phase 1)
- Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer (Phase 1)
- A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112) (Phase 3)
- Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (Phase 1)
- A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204) (Phase 3)
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas (Phase 1)
- Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis to Prevent Cytomegalovirus Disease in Lung Transplant Recipients (CYTOCOR STUDY): An Open-l (Phase 3)
- A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valyl CI brief — competitive landscape report
- Valyl updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Valyl
What is Valyl?
How does Valyl work?
What is the generic name of Valyl?
What development phase is Valyl in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing